Pharmaceutical company, Telix Pharmaceuticals (ASX:TLX) has signed a contract with US biotech company Endocyte.
The deal will see Telix provide imaging technology for Endocytes phase 3 vision trial.
The trial is an international study of the treatment of patients with progressive prostate cancer.
Telix Pharmaceuticals is a biopharmaceutical company that is developing a portfolio of clinical-stage oncology products.
Shares in Telix (ASX:TLX) are trading 4.31 per cent higher to 60 cents.